JP2015521195A - Ｔ細胞受容体を調節することができる二環式複素環およびそれを使用するための方法 - Google Patents

Ｔ細胞受容体を調節することができる二環式複素環およびそれを使用するための方法 Download PDF

Info

Publication number
JP2015521195A
JP2015521195A JP2015514534A JP2015514534A JP2015521195A JP 2015521195 A JP2015521195 A JP 2015521195A JP 2015514534 A JP2015514534 A JP 2015514534A JP 2015514534 A JP2015514534 A JP 2015514534A JP 2015521195 A JP2015521195 A JP 2015521195A
Authority
JP
Japan
Prior art keywords
alkyl
group
cycloalkyl
phenyl
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015514534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521195A5 (enExample
Inventor
ダーン ホームズ，
ダーン ホームズ，
アウケ フエルハール，
アウケ フエルハール，
デン ブリンク， ヘイス ファン
デン ブリンク， ヘイス ファン
フランチェスカ ビティ，
フランチェスカ ビティ，
Original Assignee
ノグラ ファーマ リミテッド
ノグラ ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノグラ ファーマ リミテッド, ノグラ ファーマ リミテッド filed Critical ノグラ ファーマ リミテッド
Publication of JP2015521195A publication Critical patent/JP2015521195A/ja
Publication of JP2015521195A5 publication Critical patent/JP2015521195A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015514534A 2012-06-01 2013-05-31 Ｔ細胞受容体を調節することができる二環式複素環およびそれを使用するための方法 Pending JP2015521195A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261654398P 2012-06-01 2012-06-01
US61/654,398 2012-06-01
PCT/EP2013/061328 WO2013178815A1 (en) 2012-06-01 2013-05-31 Bicyclic heterocycles capable of modulating t-cell responses, and methods of using same

Publications (2)

Publication Number Publication Date
JP2015521195A true JP2015521195A (ja) 2015-07-27
JP2015521195A5 JP2015521195A5 (enExample) 2016-07-21

Family

ID=48538005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514534A Pending JP2015521195A (ja) 2012-06-01 2013-05-31 Ｔ細胞受容体を調節することができる二環式複素環およびそれを使用するための方法

Country Status (11)

Country Link
US (2) US20150126553A1 (enExample)
EP (1) EP2861563B1 (enExample)
JP (1) JP2015521195A (enExample)
KR (1) KR20150016377A (enExample)
CN (1) CN104619687A (enExample)
AU (1) AU2013269550A1 (enExample)
BR (1) BR112014030039A2 (enExample)
CA (1) CA2874919A1 (enExample)
IN (1) IN2014DN10214A (enExample)
MX (1) MX2014014657A (enExample)
WO (1) WO2013178815A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
PT2805746T (pt) 2009-02-16 2020-08-17 Nogra Pharma Ltd Compostos de alquilamido e utilizações dos mesmos
CN116602950A (zh) 2012-02-09 2023-08-18 诺格拉制药有限公司 治疗纤维化的方法
KR20150002819A (ko) 2012-04-18 2015-01-07 노그라 파마 리미티드 락토스 불내증의 치료 방법
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
WO2017123826A1 (en) 2016-01-14 2017-07-20 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
CN112165940A (zh) * 2018-03-27 2021-01-01 德克萨斯州立大学董事会 Ox2r化合物
RS66513B1 (sr) 2019-02-08 2025-03-31 Nogra Pharma Ltd Postupak pripreme 3-(4'-aminofenil)-2-metoksipropionske kiseli-ne i njenih analoga i intermedijera
PE20230680A1 (es) * 2020-05-06 2023-04-21 Merck Sharp And Dohme Llc Inhibidores de il4i1 y metodos de uso

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1069385A1 (ru) * 1982-05-07 1990-11-15 Научно-исследовательский институт фармакологии АМН СССР Бромид 2-амино-3-(1-адамантилкарбонилметил)-1-( @ -пиперидино-этил)-бензимидазоли , обладающий способностью угнетать иммунитет
JP2005533778A (ja) * 2002-06-17 2005-11-10 メディクエスト セラピューティックス インク 麻酔薬としての、及び、神経系障害を治療するためのグアニジン化合物
WO2007024680A1 (en) * 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
WO2008036244A1 (en) * 2006-09-18 2008-03-27 The Burham Institute For Medical Research Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands
JP2008533121A (ja) * 2005-03-15 2008-08-21 ファイザー株式会社 Ｃｂ２受容体リガンドとしてのベンズイミダゾロン誘導体
JP2011513371A (ja) * 2008-03-07 2011-04-28 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体およびそのｍｃｐ−１およびｃｘ３ｃｒ１の発現に基づく疾患の治療への使用
JP2011513366A (ja) * 2008-03-07 2011-04-28 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体及びそのＭＣＰ−１，ＣＸ３ＣＲ１及びｐ４０の発現に基づく疾病の治療への使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070232673A1 (en) * 2006-01-19 2007-10-04 Roth Gregory P 2-Imino-benzimidazoles

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1069385A1 (ru) * 1982-05-07 1990-11-15 Научно-исследовательский институт фармакологии АМН СССР Бромид 2-амино-3-(1-адамантилкарбонилметил)-1-( @ -пиперидино-этил)-бензимидазоли , обладающий способностью угнетать иммунитет
JP2005533778A (ja) * 2002-06-17 2005-11-10 メディクエスト セラピューティックス インク 麻酔薬としての、及び、神経系障害を治療するためのグアニジン化合物
JP2008533121A (ja) * 2005-03-15 2008-08-21 ファイザー株式会社 Ｃｂ２受容体リガンドとしてのベンズイミダゾロン誘導体
WO2007024680A1 (en) * 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
WO2008036244A1 (en) * 2006-09-18 2008-03-27 The Burham Institute For Medical Research Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands
JP2011513371A (ja) * 2008-03-07 2011-04-28 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体およびそのｍｃｐ−１およびｃｘ３ｃｒ１の発現に基づく疾患の治療への使用
JP2011513366A (ja) * 2008-03-07 2011-04-28 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体及びそのＭＣＰ−１，ＣＸ３ＣＲ１及びｐ４０の発現に基づく疾病の治療への使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17(5), JPN6017003999, 2007, pages 1422 - 1427, ISSN: 0003495726 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 44(7), JPN6017004001, 2001, pages 1021 - 1024, ISSN: 0003495727 *

Also Published As

Publication number Publication date
US20170183313A1 (en) 2017-06-29
EP2861563A1 (en) 2015-04-22
BR112014030039A2 (pt) 2017-06-27
MX2014014657A (es) 2015-08-10
US20150126553A1 (en) 2015-05-07
IN2014DN10214A (enExample) 2015-08-07
EP2861563B1 (en) 2017-07-12
CA2874919A1 (en) 2013-12-05
KR20150016377A (ko) 2015-02-11
AU2013269550A1 (en) 2014-12-18
CN104619687A (zh) 2015-05-13
WO2013178815A1 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
JP6167173B2 (ja) Ｔ細胞受容体を調節することができる複素環およびそれを使用するための方法
JP2015521195A (ja) Ｔ細胞受容体を調節することができる二環式複素環およびそれを使用するための方法
EP2609082B1 (de) Imidazo[4,5-c]chinoline als dna-pk-inhibitoren
CN101959404B (zh) 单磷酸腺苷活化蛋白激酶调节剂
JP6991993B2 (ja) 痛覚過敏を治療する方法
US9932320B2 (en) Quinoline-based kinase inhibitors
CA2939219A1 (en) Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
CA2905993A1 (en) Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
EA020609B1 (ru) ИМИДАЗО[1,2-а]ПИРИДИН-2-ИЛФЕНИЛ ПРОИЗВОДНЫЕ ДЛЯ ЛЕЧЕНИЯ РАКА
BR112020019399A2 (pt) Compostos macrocíclicos como inibidores de trk quinases
CN115803085A (zh) 新型细胞代谢调节化合物及用途
US12448375B2 (en) Kinase inhibitors for the treatment of neurodegenerative diseases
WO2004089930A1 (en) 4-fluoroquinolone derivatives and their use as kinase inhibitors
US12453716B2 (en) Small molecule antagonist to PACAP receptor and uses thereof
CA3215697A1 (en) Soluble adenylyl cyclase (sac) inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171004